pharma 2012 introduction lec 1 final 2012
DESCRIPTION
Pharmacology introductionTRANSCRIPT
![Page 1: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/1.jpg)
PHARMACOLOGY LECTURE 1
![Page 2: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/2.jpg)
![Page 3: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/3.jpg)
Pharmacotherapeutics- refers to the use of specific drugs to prevent, treat, or diagnose a disease.
Pharmacokinetics is the study of how the body deals with the drug –its absorption, distribution, and elimination.
![Page 4: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/4.jpg)
Pharmacology is the study of drugs.
Pharmacodynamics is the analysis of what the drug does to the body, and how the drug exerts its effect.
Pharmacy deals with the preparation and dispensing of medications.
Toxicology is the study of the harmful effects of chemicals (drugs).
![Page 5: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/5.jpg)
Trade name (also known as the brand name) is assigned to the compound by the pharmaceutical company
Generic name -(also known as the “official” or “nonproprietary” name) shorter and often derived from the chemical name; the easiest and most effective way to refer to a drug,
![Page 6: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/6.jpg)
![Page 7: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/7.jpg)
When are two drugs said to be “bioequivalent”?
![Page 8: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/8.jpg)
DRUG DEVELOPMENT
Animal (preclinical) studies come first before human (clinical) testing.
Human (clinical) testing:
![Page 9: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/9.jpg)
Phase I• Determine effects, safe dosage,
pharmacokinetics• Small number (_ 100) of healthy
volunteers• < 1 year
![Page 10: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/10.jpg)
Phase II• Assess drug’s effectiveness in
treating a specific disease/disorder
• Limited number (200–300) patients with target disorder
• 2 years
![Page 11: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/11.jpg)
Phase III• Assess safety and effectiveness
in a larger patient population• Large number (1000–3000)
patients targeted• 3 yrs
![Page 12: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/12.jpg)
Phase IV (postmarketing surveillance)
• Monitor any problems that occur after NDA approval General patient population
• Indefinite
![Page 13: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/13.jpg)
nonprescription, or over-the counter (OTC); can be purchased
prescription medications may be ordered or dispensed only by an authorized practitioner (i.e., physician, dentist, or other appropriate health care provider).
![Page 14: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/14.jpg)
What can PTs do?
PTs can provide information about the proper use and potential benefits of these medications.
![Page 15: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/15.jpg)
Schedule I.
with the highest potential for abuse
not typically used as an acceptable medical treatment restricted to approved research studies or therapeutic use in a very limited number of patients
![Page 16: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/16.jpg)
Examples heroin, lysergic acid diethylamide (LSD), psilocybin, mescaline, peyote, marijuana, tetrahydrocannabinols, and several other hallucinogens.
![Page 17: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/17.jpg)
Schedule II.
approved for specific therapeutic purposes but still have a high potential for abuse and possible addiction.
Examples include opioids such as morphine and fentanyl, and drugs containing methamphetamine.
![Page 18: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/18.jpg)
Schedule III.
have a lower abuse potential than those in schedules I and II, but with the possibility of developing mild to moderate physical dependence, strong psychologic dependence, or both.
![Page 19: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/19.jpg)
certain opioids (e.g., codeine) that are combined in a limited dosage with other nonopioid drugs.
Other drugs in this category are anabolic steroids, certain barbiturates, and amphetamines that are not included in schedule II.
![Page 20: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/20.jpg)
Schedule IV.
have a lower potential for abuse than schedule III drugs, with only a limited possibility of physical dependence, psychologic dependence, or both.
![Page 21: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/21.jpg)
Examples: certain antianxiety drugs (meprobamate), certain barbiturates (barbital, phenobarbital), and a variety of other depressants and stimulants.
![Page 22: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/22.jpg)
Schedule V.
have the lowest relative abuse potential.
Examples: low doses of opioids that are used in cough medications and antidiarrheal preparations.
![Page 23: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/23.jpg)
threshold dose, the dose where the response begins to occur and continues to increase in magnitude
before reaching a plateau. The plateau indicates that there will be no further increment in the response even if the dosage continues to be increased---ceiling effect, or maximal efficacy of the drug.
![Page 24: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/24.jpg)
![Page 25: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/25.jpg)
Dose-response curves
provide information about the dosage range over which the drug is effective, as well as the peak response that can be expected from the drug.
![Page 26: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/26.jpg)
median effective dose (ED50) dose at which 50 percent of the population respond to the beneficial effects of the drug.
median toxic dose (TD50) dose at which 50 percent of the group exhibits the adverse effect
median lethal dose (LD50) .dose that causes death in 50 percent of the animals studied.
![Page 27: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/27.jpg)
![Page 28: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/28.jpg)
The median effective and toxic doses are used to determine the therapeutic index (TI).
calculated as the ratio of the TD50 to the ED50:
TI = TD50
ED50
The greater the value of the TI, the safer the drug is considered to be.
![Page 29: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/29.jpg)
Potency is related to the dose that produces a given response in a specific amplitude.
The less amount needed to produce the response, the more potent is the drug.
![Page 30: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/30.jpg)
![Page 31: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/31.jpg)
![Page 32: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/32.jpg)
All methods of drug administration that do not use the gastrointestinal tract are termed parenteral.
allows the drug to be delivered to the target site more directly
![Page 33: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/33.jpg)
Drugs will diffuse more readily through the lipid layer if they are in their neutral, nonionized form.
![Page 34: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/34.jpg)
![Page 35: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/35.jpg)
Active or carrier-mediated transport involves using membrane proteins to transport substances across the cell membrane
• Carrier specificity. • Expenditure of energy • Ability to transport substances
against a concentration gradient
![Page 36: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/36.jpg)
Facilitated Diffusion
Has features of both active transport and passive diffusion.
protein carrier is needed
But no energy is expended
inability to transport substances uphill against a concentration gradient.
![Page 37: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/37.jpg)
Entry of glucose into skeletal muscle cells via facilitated diffusion is an example
![Page 38: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/38.jpg)
The extent to which a drug is uniformly distributed depends on
• Tissue permeability. • Blood flow. • Binding to plasma proteins. • Binding to subcellular
components.
![Page 39: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/39.jpg)
storage sites of drugs:• Adipose • Bone• Muscle• Organs
![Page 40: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/40.jpg)
Very high doses of acetaminophen can react with hepatic proteins and cause severe liver damage.
![Page 41: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/41.jpg)
Controlled-release preparations,
designed to permit a slower and more prolonged absorption of the drug from the gastrointestinal tract and other routes of administration.
Advantage: decrease the number of doses needed each day
![Page 42: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/42.jpg)
Drugs are eliminated by chemically altering the original compound while still in the body so that it is no longer active (biotransformation), by excreting the active form of the drug from the body (excretion),
![Page 43: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/43.jpg)
Biotransformation usually results in an altered version of the original compound known as a metabolite, usually inactive or with reduced level of pharmacologic activity
![Page 44: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/44.jpg)
Cellular Mechanisms of Drug Biotransformation
• Oxidation• Reduction• Hydrolysis• Conjugation of the original
compound.
![Page 45: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/45.jpg)
Enzyme Induction
Prolonged use of certain drugs “induces” the body to be able to enzymatically destroy the drug more rapidly
drugs are metabolized more rapidly decreasing their therapeutic effect.
May explain why there is tolerance to some drugs (occurs when drug is used for extended periods)
![Page 46: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/46.jpg)
Tolerance refers to the need for increased drug dosages to produce the same effect.
Long-term ingestion or inhalation of other exogenous compounds such as
alcohol, cigarette smoke, or environmental toxins may cause enzyme induction
![Page 47: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/47.jpg)
Clearance of a drug refers to the ability to eliminate the drug.
Bioavailability, which is a parameter expressed as the percentage of the drug administered that reaches the bloodstream.
![Page 48: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/48.jpg)
Drug metabolism, or biotransformation, refers to chemical changes that take place in the drug following administration.
The kidneys are the primary sites for drug excretion.
![Page 49: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/49.jpg)
Half-life is defined as the amount of time required for 50 percent of the drug remaining in the body to be eliminated.
![Page 50: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/50.jpg)
Factors responsible for variations in the response to drugs:
• Genetic factors. • Disease. • Drug interactions. • Age. • Diet. • Sex
![Page 51: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/51.jpg)
Affinity -attraction between a drug and a receptor
A drug with a high affinity binds readily to receptors, even in low concentrations. Drugs with
moderate or low affinity require a higher concentration in the body before the receptors become occupied.
![Page 52: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/52.jpg)
A drug that can bind to a receptor and initiate a change in the function of the cell is referred to as an agonist.
An agonist is identified as having affinity and efficacy.
Efficacy indicates that the drug will lead to a change in the function of the cell.
![Page 53: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/53.jpg)
Whereas an agonist has both affinity and efficacy, an antagonist has only affinity.
the drug will bind to the receptor but it will not cause any direct change in the function of the receptor or cell.
![Page 54: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/54.jpg)
Antagonists are significant because, by occupying the receptor, they prevent the agonistic compound from having any effect on the cell.
Antagonists are often referred to as blockers because of their ability to block the effect of another chemical.
![Page 55: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/55.jpg)
decrease in responsiveness - desensitization due to addition of phosphate residues (phosphorylation) or some other chemical modification to the receptor protein.
![Page 56: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/56.jpg)
Receptor desensitization and down-regulation appear to be examples of a negative feedback system used by the cell to prevent overstimulation by an agonist.
![Page 57: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/57.jpg)
Receptor down-regulation describes a slower, more prolonged process in which the actual number of available receptors is diminished
![Page 58: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/58.jpg)
A prolonged decrease in the stimulation of the postsynaptic receptors can result in a functional increase in receptor sensitivity-
denervation supersensitivity
![Page 59: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/59.jpg)
seen when a peripheral nerve is severed
the lack of presynaptic neurotransmitter release results in a compensatory increase in postsynaptic receptor numbers on the muscle cell
![Page 60: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/60.jpg)
Drug tolerance is the need to take more of a drug to exert the same effect.
Dependence is described as the onset of withdrawal symptoms if drug intake is stopped.
![Page 61: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/61.jpg)
therapeutic index -used as a measure of the relative safety of the drug
![Page 62: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/62.jpg)
adverse drug event vs.adverse drug reaction
adverse drug event -“an injury resulting from the use of a drug. Under this definition, the term ADE includes harm caused by the drug (adverse drug reactions and overdoses)
adverse drug reaction -harm directly caused by the drug at normal doses, during normal use.
![Page 63: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/63.jpg)
![Page 64: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/64.jpg)
![Page 65: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/65.jpg)
![Page 66: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/66.jpg)
PRESCRIPTIONan order by a physician, for the
preparation and administration of a medicine, therapeutic regimen, assistive or corrective device, or other treatment.
![Page 67: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/67.jpg)
![Page 68: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/68.jpg)
Essential Parts of a Drug Prescription/Order:
1. Superscription consists of the heading where the symbol Rx (an abbreviation for recipe, the Latin for "take thou") is found. The RX comes before the inscription.
![Page 69: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/69.jpg)
2. Inscription- called the body of the prescription, and provides the names and quantities of the chief ingredients of the prescription. The dose and the form--tablet, suspension, capsule, syrup, etc.
![Page 70: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/70.jpg)
3. Subscription- specific directions for the pharmacist on how to compound the medication. In the old days, the pharmacist prepares the medications so directions can be "mix and place 10 capsules," "dispense 10 tablets,". Today, doctors just name the pill.
![Page 71: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/71.jpg)
4. Signatura Sig or transcription- gives instructions to the patient on how, how much, when and how long the drug is to be taken.
![Page 72: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/72.jpg)
5. Below the signatura line is room for special instructions, such as the number of times the prescription may be refilled, warnings.
![Page 73: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/73.jpg)
THE END
![Page 74: Pharma 2012 introduction lec 1 final 2012](https://reader035.vdocuments.site/reader035/viewer/2022062404/5549c0d2b4c90564768b542f/html5/thumbnails/74.jpg)